Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-12-2008 | Original Article

Principal component analysis of FDG PET in amnestic MCI

Authors: Flavio Nobili, Dario Salmaso, Silvia Morbelli, Nicola Girtler, Arnoldo Piccardo, Andrea Brugnolo, Barbara Dessi, Stig A. Larsson, Guido Rodriguez, Marco Pagani

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2008

Abstract

Purpose

The purpose of the study is to evaluate the combined accuracy of episodic memory performance and ¹⁸F-FDG PET in identifying patients with amnestic mild cognitive impairment (aMCI) converting to Alzheimer’s disease (AD), aMCI non-converters, and controls.

Methods

Thirty-three patients with aMCI and 15 controls (CTR) were followed up for a mean of 21 months. Eleven patients developed AD (MCI/AD) and 22 remained with aMCI (MCI/MCI). ¹⁸F-FDG PET volumetric regions of interest underwent principal component analysis (PCA) that identified 12 principal components (PC), expressed by coarse component scores (CCS). Discriminant analysis was performed using the significant PCs and episodic memory scores.

Results

PCA highlighted relative hypometabolism in PC5, including bilateral posterior cingulate and left temporal pole, and in PC7, including the bilateral orbitofrontal cortex, both in MCI/MCI and MCI/AD vs CTR. PC5 itself plus PC12, including the left lateral frontal cortex (LFC: BAs 44, 45, 46, 47), were significantly different between MCI/AD and MCI/MCI. By a three-group discriminant analysis, CTR were more accurately identified by PET-CCS + delayed recall score (100%), MCI/MCI by PET-CCS + either immediate or delayed recall scores (91%), while MCI/AD was identified by PET-CCS alone (82%). PET increased by 25% the correct allocations achieved by memory scores, while memory scores increased by 15% the correct allocations achieved by PET.

Conclusion

Combining memory performance and ¹⁸F-FDG PET yielded a higher accuracy than each single tool in identifying CTR and MCI/MCI. The PC containing bilateral posterior cingulate and left temporal pole was the hallmark of MCI/MCI patients, while the PC including the left LFC was the hallmark of conversion to AD.

Available only for authorised users

Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007;69:1622–34.PubMedCrossRef

Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734–46.PubMedCrossRef

Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002;59:198–205.PubMed

Loewenstein DA, Acevedo A, Agron J, Duara R. Stability of neurocognitive impairment in different subtypes of mild cognitive impairment. Dement Geriatr Cogn Disord 2007;23:82–6.PubMedCrossRef

Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183–94.PubMedCrossRef

Feldman HH, Jacova C. Mild cognitive impairment. Am J Geriatr Psychiatry 2005;13:645–55.PubMedCrossRef

Sarazin M, Berr C, De Rotrou J, Fabrigoule C, Pasquier F, Legrain S, et al. Amnestic syndrome of the medial temporal type identifies prodromal AD. A longitudinal study. Neurology 2007;69:1859–67.PubMedCrossRef

Fossati P, Harvey PO, Le BG, Ergis AM, Jouvent R, Allilaire JF. Verbal memory performance of patients with a first depressive episode and patients with unipolar and bipolar recurrent depression. J Psychiatr Res 2004;38:137–44.PubMedCrossRef

Pasquier F, Grymonprez L, Lebert F, Van der Linden M. Memory impairment differs in frontotemporal dementia and Alzheimer’s disease. Neurocase 2001;7:161–71.PubMedCrossRef

10.

Anchisi D, Borroni B, Franceschi F, Kerrouche N, Kalbe E, Beuthien-Beumann B, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005;62:1728–33.PubMedCrossRef

11.

Visser PJ, Scheltens P, Verhey FRJ, Schmand B, Launer LJ, Jolles J, et al. Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol 1999;246:477–85.PubMedCrossRef

12.

Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, et al. MCI conversion to dementia and the APOE genotype. A prediction study with FDG-PET. Neurology 2004;63:2332–40.PubMed

13.

Chetelat G, Eustache F, Viader F, De La Sayette V, Pelerin A, Mezegne F, et al. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 2005;11:14–25.PubMedCrossRef

14.

Mosconi L, Tsui WH, Pupi A, De Santi S, Drzezga A, Minoshima S, et al. 18F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer’s disease. J Nucl Med 2007;48:1129–34.PubMedCrossRef

15.

Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003;30:1104–13.PubMedCrossRef

16.

Hunt A, Schönknecht P, Henze M, Seidl U, Haberkorn U, Schröder J. Reduced cerebral glucose metabolism in patients at risk for Alzheimer’s disease. Psychiatry Res: Neuroimaging 2007;155:147–54.PubMedCrossRef

17.

Whalley LJ. Brain ageing and dementia: what makes the difference? Br J Psychiatry 2002;181:369–71.PubMedCrossRef

18.

Vandenberghe R, Tournoy J. Cognitive aging and Alzheimer’s disease. Postgrad Med J 2005;81:343–52.PubMedCrossRef

19.

Dringenberg HC. Alzheimer’s disease: more than a “cholinergic disorder”—evidence that cholinergic–monoaminergic interactions contribute to EEG slowing and dementia. Behav Brain Res 2000;115:235–49.PubMedCrossRef

20.

Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98.PubMedCrossRef

21.

Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist 1970;10:20–30.PubMed

22.

Lawton MP, Brody EM. Assessment of older people; self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179–86.PubMed

23.

Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–14.PubMed

24.

Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967–72.PubMedCrossRef

25.

Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318–22.PubMed

26.

Masur DM, Fuld PA, Blau AD, Thal LJ, Levin HS, Aronson MK. Distinguishing normal and demented elderly with selective reminding test. J Clin Exp Neuropsychol 1989;11:615–30.PubMedCrossRef

27.

Carlesimo GA, Caltagirone C, Gainotti G. The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analysis of cognitive impairment. The group for the standardization of the Mental Deterioration Battery. Eur Neurol 1996;36:378–84.PubMedCrossRef

28.

Spinnler H, Tognoni G. Standardizzazione e taratura Italiana di test neuropsicologici. Ital J Neurol Sci 1987;6(Suppl. 8):1–120.

29.

Barbarotto R, Laiacona M, Frosio R, Vecchio M, Farinato A, Capitani E. A normative study on visual reaction times and two Stroop colour-word tests. Ital J Neurol Sci 1998;19:161–70.PubMedCrossRef

30.

Watson YI, Arfken CL, Birge SJ. Clock completion: an objective screening test for dementia. J Am Geriatr Soc 1993;41:1235–40.PubMed

31.

Amodio P, Wenin H, Del Piccolo F, Mapelli D, Montagnese S, Pellegrini A, et al. Variability of trail making test, symbol digit test and line trait test in normal people. A normative study taking into account age-dependent decline and sociobiological variables. Aging Clin Exp Res 2002;14:117–31.PubMed

32.

Knopman DS, Boeve BF, Parisi JE, Dickson DW, Smith GE, Ivnik RJ. Antemortem diagnosis of frontotemporal lobar degeneration. Ann Neurol 2005;57:480–8.PubMedCrossRef

33.

Loeb C, Gandolfo C. Diagnostic evaluation of degenerative and vascular dementia. Stroke 1983;14:399–401.PubMed

34.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44.PubMed

35.

Bartenstein P, Asenbaum S, Catafau A, Halldin C, Pilowski L, Pupi A, et al. European Association of Nuclear Medicine procedure guidelines for brain imaging using [18F]FDG. Eur J Nucl Med 2002;29:BP43–BP48.

36.

Greitz T, Bohm C, Holte S, Eriksson L. A computerized brain atlas: construction, anatomical content, and some applications. J Comput Assist Tomog 1991;15:26–38.CrossRef

37.

Thurfjell L, Bohm C, Bengtsson E. CBA—an atlas based software tool used to facilitate the interpretation of neuroimaging data. Comput Methods Programs Biomed 1995;4:51–71.CrossRef

38.

Andersson JLR, Thurfjell L. Implementation and validation of a fully automatic system for intra- and inter-individual registration of PET brain scans. J Comput Assist Tomogr 1997;21:136–44.PubMedCrossRef

39.

Poulin P, Zakzanis KK. In vivo neuroanatomy of Alzheimer’s disease: evidence from structural and functional brain imaging. Brain Cogn 2002;49:220–5.PubMed

40.

Van Heertum RL, Tikofsky RS. Positron emission tomography and single photon emission computed tomography brain imaging in the evaluation of Dementia. Semin Nucl Med 2003;33:77–85.PubMedCrossRef

41.

Pett MA, Lackey NR, Sullivan JJ. Making sense of factor analysis in health care research: a practical guide. London: Sage; 2003.

42.

Rodriguez G, Nobili F, Copello F, Vitali P, Gianelli MV, Taddei G, et al. 99mTc-HMPAO regional cerebral blood flow and quantitative electroencephalography in Alzheimer’s disease: a correlative study. J Nucl Med 1999;40:522–9.PubMed

43.

Pagani M, Salmaso D, Rodriguez G, Nardo D, Larsson SA, Nobili F. Principal component analysis in mild and moderate Alzheimer’s Disease. Psychiatry Res: Neuroimaging; in press.

44.

Varrone A, Pagani M, Salvatore E, Salmaso D, Sansone V, Amboni M, et al. Identification by [99mTc]ECD SPECT of anterior cingulate hypoperfusion in progressive supranuclear palsy, in comparison with Parkinson’s disease. Eur J Nucl Med Mol Imaging 2007;34:1071–81.PubMedCrossRef

45.

Scarmeas N, Habeck CG, Zarahn E, Anderson KE, Park A, Hilton J, et al. Covariance PET patterns in early Alzheimer’s disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance. NeuroImage 2004;23:35–45.PubMedCrossRef

46.

Salmon E, Kerrouche N, Perani D, Lekeu F, Holthoff V, Beuthien-Baumann B, et al. On the multivariate nature of brain metabolic impairment in Alzheimer’s disease. Neurobiol Aging 2007; July 23; epub ahead of print.

47.

Mosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska L, et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry 2008;63:609–18.PubMedCrossRef

48.

Liddell BJ, Paul RH, Arns M, Gordon N, Kukla M, Rowe D, et al. Rates of decline distinguish Alzheimer’s disease and mild cognitive impairment relative to normal aging: integrating cognition and brain function. J Integr Neurosci 2007;6:141–74.PubMedCrossRef

49.

Kantarci K, Jack CR Jr. Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am 2003;13:197–209.PubMedCrossRef

50.

Mesulam MM, Shaw P, Mash D, et al. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 2004;55:815–28.PubMedCrossRef

51.

Blennow K, De Leon M, Zetterberg H. Alzheimer’s disease. Lancet 2006;368:387–403.PubMedCrossRef

52.

Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and 18F-FDG PET. J Nucl Med 2005;46:1625–32.PubMed

53.

DeCarli C. Mild cognitive impairment: diagnosis, prognosis, aetiology, and treatment. Lancet Neurol 2003;2:15–21.PubMedCrossRef

54.

de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucosey positron-emission tomography (FDG PET). Proc Natl Acad Sci USA 2001;98:10966–71.PubMedCrossRef

55.

Chetelat G, Landeau B, Eustache F, Mezenge F, Viader F, de la Sayette V, et al. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: A longitudinal MRI study. NeuroImage 2005;27:934–46.PubMedCrossRef

56.

Ringman JM, O’Neill J, Geschwind D, Medina L, Apostolova LG, Rodriguez Y, et al. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer’s disease mutations. Brain 2007;130:1767–76.PubMedCrossRef

57.

Braak H, Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol (Berl) 1996;92:197–201.CrossRef

58.

Bartzokis G, Sultzer D, Lu PH, Nuechterlein KH, Mintz J, Cummings JL. Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical “disconnection” in aging and Alzheimer’s disease. Neurobiol Aging 2004;25:843–51.PubMedCrossRef

59.

Cabeza R, Nyberg L. Imaging cognition. II. An empirical review of 275 PET and fMRI studies. J Cogn Neurosci 2000;12:1–47.PubMedCrossRef

60.

Simic G, Bexheti S, Kelovic Z, Kos M, Grbic K, Hof PR, et al. Hemispheric asymmetry, modular variability and age-related changes in the human entorhinal cortex. Neuroscience 2005;130:911–925.PubMedCrossRef

61.

Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, Convit A, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 2005;64:1860–7.PubMedCrossRef

Title: Principal component analysis of FDG PET in amnestic MCI
Authors: Flavio Nobili
Dario Salmaso
Silvia Morbelli
Nicola Girtler
Arnoldo Piccardo
Andrea Brugnolo
Barbara Dessi
Stig A. Larsson
Guido Rodriguez
Marco Pagani
Publication date: 01-12-2008
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0869-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Principal component analysis of FDG PET in amnestic MCI

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2008

The effect of education on rCBF changes in Alzheimer’s disease: a longitudinal SPECT study

Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies

Announcement

Required time delay from 99mTc-HMPAO injection to SPECT data acquisition: healthy subjects and patients with rCBF pattern

The molecular background of sex difference in depressive disorders: still an enigma

Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage